Enter your Email address:
Wolters Kluwer Health may email you for journal alerts and information, but is committed
to maintaining your privacy and will not share your personal information without
You currently have no recent searches
Sinaasappel, M.1; Van der Wegen, P.2; Louwen, R.2; Imam, A.2; Grosveld, F.2; Scholte, B.2
1Pediatric Gastroenterology, ErasmusMC location Sophia, 2Cell biology, Erasmus MC, Rotterdam, Netherlands
Submitted by: firstname.lastname@example.org
Introduction: Treatment of congenital and acquired liver disease is one of the main issues in the field of gene therapy. HIV-1 derived lentiviral vectors of the latest generation have several potential advantages over alternative systems. We have tested such a vector in a rat model (Gunn rat) of Crigler-Najjar disease (CN). CN is a recessive inherited disorder in humans characterized by chronic severe jaundice. CN is caused by mutations in the bilirubin UDP glycosyltransferase gene (hUGT1A1) that is involved in the clearance of heme metabolites in the liver. Present treatment by light therapy is cumbersome and insufficient. The only known effective remedy is liver transplantation, which requires high-risk surgery and cyclosporin treatment. Therefore, gene therapy is considered as an alternative.
Methods: We have constructed and produced a self-inactivating VSV-G pseudotyped lentiviral vector LV ALBUGT, which is designed to express the human UGT1A1 gene specifically in liver parenchymal cells. Juvenile Gunn rats were treated with this preparation by intravenous injection (108–109 transforming units).
Results: Eight weeks after treatment with the highest vector dose we observed a complete normalisation of bilirubin levels, and normal secretion of bilirubin conjugates in the bile, in contrast to untreated animals. In situ hybridisation showed expression of the therapeutic gene in up to thirty percent of liver parenchymal cells. No adverse effects, such as transient inflammation morbidity or mortality, were observed.
Conclusion: To our knowledge this is the first demonstration in an animal model of complete remission of a congenital liver disease, after systemic application of a lentiviral vector. These encouraging results suggest that clinical application of this vector would be feasible
© 2004 Lippincott Williams & Wilkins, Inc.
Colleague's E-mail is Invalid
Your Name: (optional)
Separate multiple e-mails with a (;).
Thought you might appreciate this item(s) I saw at Journal of Pediatric Gastroenterology and Nutrition.
Send a copy to your email
Your message has been successfully sent to your colleague.
Some error has occurred while processing your request. Please try after some time.
An Existing Folder
A New Folder
The item(s) has been successfully added to "".
Login with your LWW Journals username and password.
Username or Email:
Enter and submit the email address you registered with. An email with instructions to reset your password will be sent to that address.
Link to reset your password has been sent to specified email address.
What does "Remember me" mean?
By checking this box, you'll stay logged in until you logout. You'll get easier access to your articles, collections,
media, and all your other content, even if you close your browser or shut down your
To protect your most sensitive data and activities (like changing your password),
we'll ask you to re-enter your password when you access these services.
What if I'm on a computer that I share with others?
If you're using a public computer or you share this computer with others, we recommend
that you uncheck the "Remember me" box.
Save my selection
Visit JPGN.org on your smartphone. Scan this code (QR reader app required) with your phone and be taken directly to the site.